Charchar Fj, Zimmerli Lu, Tomaszewski M
Department of Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK.
J Hum Hypertens. 2008 Dec;22(12):821-8. doi: 10.1038/jhh.2008.67. Epub 2008 Jul 17.
Researchers in hypertension genetics feel like they are left behind again. It always seems that the 'other' complex diseases are ahead in the race. Evolving new technologies in the form of genome-wide arrays and 'omics' technologies mean that investigators can now potentially identify many novel disease factors in one large-scale experiment. Hypertension research now faces the challenge of where to go next after the first genome-wide association experiments failed to provide robust candidates. In this review, we contemplate the old dilemma of whether such genes may ever be found; however, we believe advancing technologies and plummeting costs of large-scale experiments will contribute to the identification of novel molecules that underlie essential hypertension.
高血压遗传学领域的研究人员感觉自己又被落在了后面。似乎总是“其他”复杂疾病在这场竞赛中领先。全基因组阵列和“组学”技术等不断发展的新技术意味着，研究人员现在有可能在一项大规模实验中识别出许多新的疾病因素。在首次全基因组关联实验未能提供有力候选基因之后，高血压研究如今面临下一步该何去何从的挑战。在这篇综述中，我们思考了是否能找到此类基因这一由来已久的难题；然而，我们相信技术的进步以及大规模实验成本的大幅下降将有助于识别出构成原发性高血压基础的新分子。
